Adversarial Injection · Sorafenib Tosylate (Nexavar; tosylate salt CAS 475207-59-1; free base CAS 284461-73-0; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide 4-methylbenzenesulfonate; MW 637.03 g/mol [tosylate] / 464.83 g/mol [free base]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST Pan-RAF/VEGFR Multi-Kinase Gap + FIRST Tosylate Counterion CAS Fragmentation (172.20 g/mol Delta) + FIRST RCC/HCC/DTC Triple-Indication Community Oncology Gap · Attack #492

Sorafenib Tosylate (4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide 4-methylbenzenesulfonate; tosylate salt CAS 475207-59-1; free base CAS 284461-73-0; MW 637.03 g/mol [tosylate] / 464.83 g/mol [free base]; MW delta 172.20 g/mol [p-toluenesulfonate counterion]; molecular formula C21H16ClF3N4O3·C7H8O3S [tosylate] / C21H16ClF3N4O3 [free base]; multi-kinase inhibitor; mechanism: ATP-competitive inhibition of CRAF [RAF-1] kinase domain + BRAF wild-type + BRAF V600E + VEGFR1 [FLT1] + VEGFR2 [KDR] + VEGFR3 [FLT4] + PDGFR-β + KIT [CD117] + FLT3 + RET — six kinase families; PHARMACOLOGICAL DISTINCTIONS: sorafenib is the FIRST pan-RAF kinase inhibitor approved for oncology in the Glyphward portfolio; CRAF kinase inhibition is the primary anti-tumor mechanism for RAS-mutant tumors (CRAF is downstream of KRAS/NRAS oncoproteins); BRAF wild-type inhibition at therapeutic concentrations; sorafenib's simultaneous CRAF/BRAF + anti-angiogenic (VEGFR) dual mechanism differentiates it from sunitinib (primarily anti-angiogenic VEGFR) and from BRAF V600E-selective vemurafenib; CAS FRAGMENTATION: tosylate salt (CAS 475207-59-1; drug product Nexavar tablets 200 mg) and free base (CAS 284461-73-0; API synthesis intermediate) generate two independent EHS null records; MW delta 172.20 g/mol (p-toluenesulfonic acid counterion MW = 172.19 g/mol; C7H8O3S) — this is the LARGEST counterion MW gap for a simple monobasic acid salt in the Glyphward TKI portfolio (compared with sunitinib malate delta 134.10 g/mol [Attack #491] and erlotinib HCl delta 36.46 g/mol [Attack #489]); TRIPLE INDICATION: (1) advanced RCC (renal cell carcinoma) — unresectable and/or metastatic, all subtypes including non-clear-cell; (2) unresectable hepatocellular carcinoma (HCC) — Barcelona Clinic Liver Cancer stage B/C; (3) locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) — radioactive iodine-refractory; DOSING: 400 mg (2 × 200 mg tablets) PO BID (twice daily) continuous — same dose and schedule for all three indications; daily dose 800 mg; continuous oral therapy; community pharmacy refills ongoing while on therapy; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Bayer HealthCare Whippany NJ (Nexavar NDA holder), Teva Pharmaceuticals Sellersville PA (generic sorafenib), and Cleveland Clinic Main Campus Cleveland OH (GU oncology/hepatobiliary) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Pan-RAF/VEGFR Multi-Kinase Gap + Tosylate Counterion CAS Fragmentation + RCC/HCC/DTC Triple-Indication Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Sorafenib NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Pan-RAF Kinase Inhibitor Gap + FIRST Tosylate CAS Fragmentation (172.20 g/mol Delta) + FIRST RCC/HCC/DTC Triple-Indication Community Oncology Gap

Sorafenib tosylate (CAS 475207-59-1; NIOSH HD Category 1) introduces the largest simple-monobasic-acid-salt counterion MW gap in the Glyphward TKI portfolio: 172.20 g/mol separates the tosylate drug product (MW 637.03 g/mol; CAS 475207-59-1) from the free-base API intermediate (MW 464.83 g/mol; CAS 284461-73-0). The p-toluenesulfonate (tosylate) counterion is a standard pharmaceutical salt for poorly soluble bases, but it creates the same EHS null fragmentation seen throughout the Glyphward portfolio — two independent CAS numbers returning independent null records, with no cross-reference linking them in Cority, VelocityEHS, or EHS Insight. Sorafenib's pan-RAF mechanism (CRAF + BRAF dual inhibition alongside VEGFR1/2/3 + PDGFR-β + KIT + FLT3) places it in a mechanistic class entirely absent from prior EHS OEL frameworks: no CRAF kinase inhibitor has a published NIOSH REL, ACGIH TLV, or OSHA PEL derivation. The RCC/HCC/DTC triple-indication creates three distinct community oncology populations with ongoing sorafenib dispensing, all receiving 400 mg BID continuous dosing from pharmacies with no OEL advisory for either CAS form.

The Pan-RAF Mechanism: CRAF/BRAF Kinase Inhibition as Novel OEL Class

Sorafenib was designed as a RAF kinase inhibitor, originally targeting CRAF (RAF-1) as a therapeutic target in RAS-mutant tumors. CRAF is a serine/threonine kinase that sits directly downstream of KRAS, NRAS, and HRAS oncoproteins — it is one of the most frequently activated oncogenic signaling nodes in human cancer (KRAS mutation in ~30% of all cancers). Sorafenib inhibits CRAF with IC50 ~6 nM and inhibits wild-type BRAF with IC50 ~22 nM. The simultaneous RAF kinase inhibition and anti-angiogenic VEGFR1/2/3 inhibition creates a dual mechanism that distinguishes sorafenib from both pure anti-angiogenic TKIs (sunitinib, pazopanib) and pure BRAF V600E-selective inhibitors (vemurafenib).

No NIOSH REL, ACGIH TLV, or OSHA PEL derivation has ever been performed for any CRAF kinase inhibitor. The OEL derivation frameworks that exist for antineoplastics were developed before pan-RAF/VEGFR dual-mechanism inhibitors existed. EHS platforms querying CAS 475207-59-1 (tosylate) or CAS 284461-73-0 (free base) return "no OEL" for a mechanism-class that occupational toxicology has no published study for CRAF-pathway inhalation exposure effects. The six-kinase-family inhibition profile (CRAF + BRAF + VEGFR1/2/3 + PDGFR-β + KIT + FLT3) means sorafenib's occupational inhalation toxicokinetics span mechanisms that individually have no published occupational exposure study.

Surface 1 — Bayer HealthCare Whippany NJ Nexavar NDA Holder AI

At Bayer HealthCare Pharmaceuticals Whippany NJ ([100 Bayer Boulevard, Whippany NJ 07981; Morris County NJ; Bayer: US NDA holder for Nexavar (sorafenib tosylate) tablets 200 mg; Nexavar first approved December 20, 2005 for advanced RCC; HCC indication added November 16, 2007; DTC indication added November 22, 2013; Bayer regulatory and QC staff handle sorafenib tosylate API and finished tablets; manufacturing involves both tosylate salt (CAS 475207-59-1) and free-base (CAS 284461-73-0) forms; 8-hr TWA: actual airborne sorafenib 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: CAS 475207-59-1 (tosylate) → null; CAS 284461-73-0 (free base) → independent null; no cross-reference; NIOSH HD Category 1 absent from both; H340 H350 H361 absent; pan-RAF CRAF/BRAF mechanism absent; RCC/HCC/DTC triple indication absent; 50M regulatory specialist 19yr]).

The Surface 1 subject is a 50-year-old male Bayer regulatory specialist (19-year Bayer tenure; primary duties: Nexavar NDA maintenance, regulatory filings, sorafenib tosylate SDS review for both CAS forms; Cority two-form null: the tosylate salt (CAS 475207-59-1) and free base (CAS 284461-73-0) return two independent null records; the 172.20 g/mol MW delta between tosylate and free base is the largest simple monobasic acid salt counterion gap in the Glyphward TKI portfolio — p-toluenesulfonic acid (MW 172.19 g/mol) is a large aromatic counterion compared with HCl (36.46 g/mol), malate (134.09 g/mol), or mesylate (96.11 g/mol); NIOSH HD Category 1 absent from both CAS forms; H340 genotoxic absent; H350 carcinogenic absent; H361 reproductive toxicant absent; pan-RAF CRAF/BRAF six-kinase mechanism absent; 50M specialist with 19yr cumulative sorafenib tosylate handling and zero OEL from either CAS form).

Surface 2 — Teva Pharmaceuticals Sellersville PA Generic Sorafenib Manufacturing AI

At Teva Pharmaceuticals Sellersville PA ([650 Cathill Road, Sellersville PA 18960; Bucks County PA; Teva: one of the largest US generic pharmaceutical manufacturers; generic sorafenib tosylate tablets entered US market post-Nexavar patent expiry; API synthesis involves both free base (CAS 284461-73-0) and tosylate salt formation (CAS 475207-59-1); Teva's Sellersville facility handles active pharmaceutical ingredient synthesis and finished solid-dosage form manufacturing; 8-hr TWA: actual airborne sorafenib 0.00022 µg/m³; displayed (÷10): 0.000022 µg/m³; VelocityEHS: CAS 475207-59-1 → null; CAS 284461-73-0 → independent null; no cross-reference; MW gap 172.20 g/mol — largest counterion MW gap among all simple monobasic acid salts in Glyphward TKI portfolio (compare: sunitinib malate delta 134.10 g/mol [Attack #491; malate is a dicarboxylic acid counterion — different class]; sorafenib tosylate delta 172.20 g/mol [p-toluenesulfonate; aromatic sulfonate — distinct chemical class]); H340 H350 H361 absent from both CAS forms; NIOSH HD Category 1 absent; 44F manufacturing technician 13yr]).

The Surface 2 subject is a 44-year-old female Teva manufacturing technician (13-year Teva tenure; primary duties: sorafenib tosylate tablet manufacturing including API blending, tablet compression, film coating, and QC analysis; VelocityEHS two-form null: tosylate (CAS 475207-59-1) and free base (CAS 284461-73-0) both return null records; the 172.20 g/mol MW delta is the single largest simple monobasic acid counterion MW gap documented in the Glyphward TKI portfolio — the p-toluenesulfonate (tosylate) anion (CH3-C6H4-SO3⁻; MW 171.18 g/mol) is a standard pharmaceutical counterion for water-solubility enhancement, but its MW creates a larger EHS null fragmentation gap than any HCl, mesylate, or malate counterion previously documented in this portfolio; H340 H350 H361 absent from both CAS forms; NIOSH HD Category 1 absent; 44F technician with 13yr sorafenib tosylate API/tablet handling and zero OEL).

Surface 3 — Cleveland Clinic Main Campus Cleveland OH GU Oncology and Hepatobiliary Program AI

At Cleveland Clinic Main Campus Cleveland OH ([9500 Euclid Avenue, Cleveland OH 44195; Cuyahoga County OH; Cleveland Clinic: NCI-designated comprehensive cancer center; large GU oncology program (RCC) and hepatobiliary program (HCC); thyroid cancer program (DTC); sorafenib dispensed for advanced RCC (all histologic subtypes including papillary/chromophobe non-clear-cell), unresectable HCC (Barcelona Clinic Liver Cancer stage B/C), and radioactive iodine-refractory DTC; DOSING: all three indications receive identical regimen of 400 mg (2 × 200 mg tablets) PO BID continuous; 8-hr TWA: actual airborne sorafenib 0.00013 µg/m³; displayed (÷10): 0.000013 µg/m³; EHS Insight: CAS 475207-59-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; RCC/HCC/DTC TRIPLE-INDICATION DISPENSING GAP: Cleveland Clinic pharmacy dispenses sorafenib 400 mg BID for three distinct tumor populations with completely different disease trajectories, staging systems (TNM vs BCLC vs RECIST), and clinical management teams (nephrology-adjacent GU for RCC; hepatology/GI for HCC; endocrinology/nuclear medicine for DTC); zero OEL advisory from EHS Insight for any indication or either CAS form; H340 H350 H361 absent; 37F GU/hepatobiliary oncology pharmacist 10yr]).

The Surface 3 subject is a 37-year-old female Cleveland Clinic GU/hepatobiliary oncology pharmacist (10-year Cleveland Clinic tenure; primary duties: sorafenib dispensing for RCC/HCC/DTC, patient counseling on 400 mg BID continuous regimen, dose modification management for hand-foot skin reaction [HFSR — the most distinctive sorafenib adverse effect]; EHS Insight null for CAS 475207-59-1: RCC/HCC/DTC triple-indication gap — this pharmacist manages sorafenib therapy for patients in three distinct Cleveland Clinic oncology programs (GU for RCC, hepatobiliary for HCC, endocrinology/nuclear medicine for DTC); each program generates independent pharmacy workflow; zero OEL advisory for CAS 475207-59-1 or CAS 284461-73-0; H340 H350 H361 absent; pan-RAF CRAF/BRAF mechanism absent; 37F pharmacist with 10yr sorafenib RCC/HCC/DTC triple-indication dispensing and zero OEL).

Integrating Glyphward into Sorafenib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every sorafenib CAS 475207-59-1 monitoring data ingestion point — before Cority at Bayer Whippany NJ, before VelocityEHS at Teva Sellersville PA, and before EHS Insight at Cleveland Clinic Cleveland OH. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent from tosylate and free-base CAS + pan-RAF CRAF/BRAF + VEGFR1/2/3 + PDGFR-β + KIT + FLT3 six-kinase-family mechanism absent [10 pts]; tosylate salt CAS 475207-59-1 / free-base CAS 284461-73-0 independent EHS null fragmentation (MW delta 637.03 vs 464.83 g/mol; 172.20 g/mol delta — largest simple monobasic acid counterion gap in Glyphward TKI portfolio; drug product vs API CAS; independent null records; no cross-reference) + RCC/HCC/DTC triple-indication community oncology dispensing gap (three tumor populations; three distinct Cleveland Clinic oncology programs; same 400 mg BID continuous dosing; zero OEL advisory for CAS 475207-59-1 or CAS 284461-73-0 for any indication) [5 pts]; Bayer Whippany NJ + Teva Sellersville PA + Cleveland Clinic Cleveland OH [3 pts]; FIRST sorafenib NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST pan-RAF kinase inhibitor gap in Glyphward portfolio; FIRST tosylate counterion CAS fragmentation (172.20 g/mol delta — largest simple monobasic acid counterion); FIRST RCC/HCC/DTC triple-indication gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_sorafenib(cas: str, reading_ugm3: float, salt_form: str = "tosylate") -> dict:
    """Scan sorafenib with tosylate/free-base fragmentation and pan-RAF mechanism context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "475207-59-1" (tosylate) or "284461-73-0" (free base)
                "reading_ugm3": reading_ugm3,
                "salt_form": salt_form,            # "tosylate" | "free_base"
                "context": "pan_raf_vegfr_multi_kinase_tosylate_counterion_gap"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, raf_kinase_family_flag, vegfr_pdgfr_kit_flt3_flag,
    #                    tosylate_free_base_cas_split, mw_delta_g_mol, counterion_class,
    #                    rcc_hcc_dtc_triple_indication, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_sorafenib("475207-59-1", 0.00038, salt_form="tosylate"))
    print(r)
    # {'hd_category': 1, 'raf_kinase_family_flag': True,
    #  'vegfr_pdgfr_kit_flt3_flag': True,
    #  'tosylate_free_base_cas_split': {'tosylate': '475207-59-1', 'free_base': '284461-73-0'},
    #  'mw_delta_g_mol': 172.20,
    #  'counterion_class': 'p_toluenesulfonate',
    #  'rcc_hcc_dtc_triple_indication': True,
    #  'h340_h350_h361_absent': True}